OncoMatch/Clinical Trials/NCT04437329
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
Is NCT04437329 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Docetaxel, nedaplatin, fluorouracil and Docetaxel, cisplatin, fluorouracil for nasopharyngeal carcinoma.
Treatment: Docetaxel, nedaplatin, fluorouracil · Docetaxel, cisplatin, fluorouracil · Nedaplatin · Cisplatin — To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Excluded: Stage T3-4N0
Performance status
KARNOFSKY 70–100
KARNOFSKY scale (KPS) > 70
Prior therapy
Cannot have received: radiotherapy
Exception: diagnostic surgery allowed
History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes
Cannot have received: chemotherapy
Exception: diagnostic surgery allowed
History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes
Cannot have received: surgery
Exception: diagnostic surgery allowed
History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes
Lab requirements
Blood counts
WBC ≥ 4×10^9/l, platelet ≥ 100×10^9/l, hemoglobin ≥ 90g/l
Kidney function
creatinine ≤ 1.5×uln or ccr ≥ 60ml/min
Liver function
TBIL, ALT, AST ≤ 2.5×uln
WBC≥4×10^9/ l, platelet ≥ 100×10^9/ l and hemoglobin ≥ 90g/l; normal liver function test (TBIL、ALT、AST ≤ 2.5×uln); normal renal function test (creatinine ≤ 1.5×uln or ccr ≥ 60ml/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify